RESUMO
OBJECTIVE: To evaluate the effectiveness of canine parvovirus monoclonal antibody (CPMA) as a treatment against canine parvovirus (CPV-2)-induced mortality and to support USDA product licensure. ANIMALS: 28 purpose-bred Beagle dogs aged 8 weeks were randomized to the treated (n = 21) or control (7) group. METHODS: Dogs were challenged intranasally with 104.2 TCID50 virulent CPV-2b on Day 0 and monitored for 14 days for fecal viral shed and clinical disease. All dogs began shedding CPV-2 on Day 4 and were treated intravenously with a single dose of either CPMA (0.2 mL/kg) or saline (equal volume). No additional treatments were given to either group. Feces and sera were collected for quantitative analysis of fecal viral shed (hemagglutination) and antibody responses (hemagglutination inhibition and dot-blot ELISA), respectively. Dogs were monitored twice daily for parameters including lymphopenia, fever, vomiting, abnormal feces, inappetence, and lethargy. Humane endpoints triggered euthanasia by a veterinarian masked to treatment groups. The primary outcome variable was prevention of mortality as compared to controls. RESULTS: Mortality was prevented in all CPMA-treated dogs compared to 57% mortality in the control group (P = .0017, Fisher exact test). Canine parvovirus monoclonal antibody-treated dogs also experienced less severe and/or shorter durations of diarrhea, fever, vomiting, CPV-2 shedding in feces, and lymphopenia. Both groups showed similar immunoglobulin M responses as measured by semiquantitative analysis. CLINICAL RELEVANCE: Intravenous administration of CPMA can effectively improve clinical outcome when administered early in CPV-2 disease. Canine parvovirus monoclonal antibody treatment after proven infection does not interfere with adaptive immunity.
Assuntos
Doenças do Cão , Linfopenia , Infecções por Parvoviridae , Parvovirus Canino , Animais , Cães , Anticorpos Antivirais , Infecções por Parvoviridae/veterinária , Doenças do Cão/tratamento farmacológico , Doenças do Cão/prevenção & controle , Vômito/veterinária , Fezes , Linfopenia/veterinária , Anticorpos Monoclonais/uso terapêuticoRESUMO
Twelve cats were vaccinated at 8 and 11 weeks of age with a commercially available inactivated FeLV vaccine (Nobivac FeLV, Intervet/Schering-Plough Animal Health). Eleven cats served as age-matched, placebo-vaccinated controls. All cats were kept in isolation for 2 years after vaccination and were then challenged with virulent FeLV to evaluate vaccine efficacy and duration of immunity. Cats were monitored for 12 weeks after challenge for development of persistent viremia using a commercial FeLV p27 ELISA. Persistent viremia developed in all 11 (100%) of the control cats, whereas 10 of 12 (83%) vaccinated cats were fully protected from persistent viremia following challenge. The results demonstrate that the vaccine used in this study protects cats from persistent FeLV viremia for at least 2 years after vaccination.
Assuntos
Vírus da Leucemia Felina/imunologia , Leucemia Felina/prevenção & controle , Vacinas Virais/imunologia , Animais , Gatos , Organismos Livres de Patógenos Específicos , Vacinação , Vacinas de Produtos Inativados/imunologia , ViremiaRESUMO
Canine influenza virus (CIV) subtype H3N8 has emerged as a new pathogen with sustained transmission in the dog population in the United States. In this study, we report the experimental induction of respiratory disease in dogs using three CIV field isolates. Young (14 to 15 weeks of age) CIV-seronegative pups were challenged with one of three CIV isolates and monitored for clinical signs of respiratory disease, nasal virus shedding, seroconversion, lung lesions, and virus isolation from the lower respiratory tract. The challenged pups developed clinical signs and lung lesions typical of influenza virus infection, shed virus in their nasal secretions for 7 to 8 days after challenge, and exhibited serum antibodies at 7 and 14 days after challenge. Lung tissues and tracheal swabs collected at 3 and 6 days after challenge exhibited active virus replication. These results demonstrate that CIV causes respiratory disease in dogs.
Assuntos
Doenças do Cão/virologia , Vírus da Influenza A Subtipo H3N8 , Infecções por Orthomyxoviridae/veterinária , Animais , Anticorpos Antivirais/sangue , Doenças do Cão/patologia , Cães , Feminino , Pulmão/patologia , Masculino , Infecções por Orthomyxoviridae/patologia , Infecções por Orthomyxoviridae/virologia , Replicação ViralRESUMO
Canine influenza virus (CIV) subtype H3N8 is an emerging pathogen with sustained horizontal transmission in the dog population in the United States. This study evaluated the efficacy of an inactivated CIV vaccine in 6- to 8-week-old beagle pups challenged with virulent CIV. One group of CIV-seronegative pups was vaccinated with two doses of a CIV vaccine 3 weeks apart; a second group of pups received adjuvanted placebo as a control. Blood samples were collected at various times to determine antibody titers. All pups were challenged with a virulent CIV isolate 13 days after the second vaccination and monitored for clinical signs of respiratory disease, virus shedding, and lung consolidation. Vaccinated pups developed hemagglutination inhibition antibody titers after vaccination. The severity of clinical signs (P < .001) and the magnitude and duration of virus shedding (P < .0001) were significantly lower in vaccinated pups compared with control pups. These results demonstrate that the CIV vaccine used in this study provides protection against virulent CIV challenge in dogs.
Assuntos
Doenças do Cão/prevenção & controle , Vírus da Influenza A Subtipo H3N8/imunologia , Vacinas contra Influenza/normas , Infecções por Orthomyxoviridae/veterinária , Animais , Anticorpos Antivirais/sangue , Antígenos Virais/análise , Cães , Feminino , Testes de Inibição da Hemaglutinação/veterinária , Imuno-Histoquímica/veterinária , Vírus da Influenza A Subtipo H3N8/isolamento & purificação , Vacinas contra Influenza/imunologia , Pulmão/patologia , Pulmão/virologia , Masculino , Infecções por Orthomyxoviridae/patologia , Infecções por Orthomyxoviridae/prevenção & controle , Infecções por Orthomyxoviridae/virologia , Vacinas de Produtos Inativados/imunologia , Vacinas de Produtos Inativados/normas , Eliminação de Partículas ViraisRESUMO
Antibody levels to outer surface proteins C and F (OspC and OspF, respectively) in sera collected from laboratory Beagle dogs at 1, 2, and 4 months after challenge with infected black-legged ticks (Ixodes scapularis) were determined. Each dog was confirmed by culture to harbor Borrelia burgdorferi in the skin (n = 10) or the skin and joints (n = 14). Significant levels of immunoglobulin M (Ig)M or IgG anti-OspC antibodies were detected in single serum samples from only 3 (13%) dogs. Similarly, IgM anti-OspF antibodies were detected in only 1 (4%) serum sample collected from a dog with B. burgdorferi in the skin and joints. In contrast, 4 (29%) dogs with skin and joint infections produced IgG anti-OspF antibodies after 2 months, and the response expanded to include 2 (20%) dogs with skin infection and 4 additional dogs with skin and joint infections (overall sensitivity = 62%) after 4 months. The findings failed to support the utility of OspC-based antibody tests for diagnosing canine Lyme disease, but demonstrated that dogs with B. burgdorferi colonizing joint tissue most often produced significant levels of IgG anti-OspF antibodies. Therefore, additional studies to more thoroughly evaluate the clinical utility of OspF-based antibody tests are warranted.
Assuntos
Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/imunologia , Proteínas da Membrana Bacteriana Externa/imunologia , Borrelia burgdorferi/imunologia , Doenças do Cão/diagnóstico , Lipoproteínas/imunologia , Doença de Lyme/veterinária , Animais , Formação de Anticorpos , Doenças do Cão/microbiologia , Cães , Feminino , Ixodes/microbiologia , Doença de Lyme/diagnóstico , MasculinoRESUMO
Beagles received placebo or ospA- and ospB-negative Borrelia burgdorferi before a tick challenge. A total of 28 (41%) ticks and skin biopsy specimens from each control dog (n = 10) contained B. burgdorferi. In contrast, 12 (19%) ticks recovered from the vaccine recipients (n = 10) were infected (P = 0.0077), and 5 dogs yielded spirochetes from the skin biopsy specimens (P = 0.0325). In addition, 9 (90%) placebo recipients and 4 (40%) vaccine recipients developed joint abnormalities (P = 0.0573). Therefore, vaccination with the ospA- and ospB-negative spirochete provided significant protection against Lyme disease.
Assuntos
Vacinas Bacterianas/imunologia , Borrelia burgdorferi/imunologia , Doenças do Cão/imunologia , Doenças do Cão/prevenção & controle , Doença de Lyme/veterinária , Vacinação/métodos , Animais , Antígenos de Bactérias/genética , Antígenos de Superfície , Proteínas da Membrana Bacteriana Externa/genética , Vacinas Bacterianas/administração & dosagem , Vacinas Bacterianas/genética , Borrelia burgdorferi/genética , Cães , Lipoproteínas/deficiência , Doença de Lyme/imunologia , Doença de Lyme/prevenção & controle , Placebos , Resultado do Tratamento , Vacinas Atenuadas/administração & dosagem , Vacinas Atenuadas/genética , Vacinas Atenuadas/imunologiaRESUMO
OBJECTIVE: To determine the ability of a modified-live virus (MLV) bovine viral diarrhea virus (BVDV) type 1 (BVDV1) vaccine administered to heifers prior to breeding to stimulate protective immunity that would block transmission of virulent heterologous BVDV during gestation, thus preventing persistent infection of a fetus. ANIMAL: 40 crossbred Angus heifers that were 15 to 18 months old and seronegative for BVDV and 36 calves born to those heifers. PROCEDURE: Heifers were randomly assigned to control (n = 13) or vaccinated (27) groups. The control group was administered a multivalent vaccine where-in the BVDV component had been omitted. The vaccinated heifers were administered a single dose of vaccine (IM or SC) containing MLV BVDV1 (WRL strain). All vaccinated and control heifers were maintained in pastures and exposed to BVDV-negative bulls 21 days later. Thirty-five heifers were confirmed pregnant and were challenge exposed at 55 to 100 days of gestation by IV administration of virulent BVDV1 (7443 strain). RESULTS: All control heifers were viremic following challenge exposure, and calves born to control heifers were persistently infected with BVDV. Viremia was not detected in the vaccinated heifers, and 92% of calves born to vaccinated heifers were not persistently infected with BVDV. CONCLUSIONS AND CLINICAL RELEVANCE: These results document that vaccination with BVDV1 strain WRL protects fetuses from infection with heterologous virulent BVDV1.
Assuntos
Doença das Mucosas por Vírus da Diarreia Viral Bovina/prevenção & controle , Vírus da Diarreia Viral Bovina Tipo 1/imunologia , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Transmissão Vertical de Doenças Infecciosas/veterinária , Vacinas Virais/imunologia , Animais , Doença das Mucosas por Vírus da Diarreia Viral Bovina/imunologia , Doença das Mucosas por Vírus da Diarreia Viral Bovina/fisiopatologia , Bovinos , Vírus da Diarreia Viral Bovina Tipo 1/isolamento & purificação , Feminino , Feto/virologia , Gravidez , Complicações Infecciosas na Gravidez/prevenção & controle , Complicações Infecciosas na Gravidez/veterinária , Complicações Infecciosas na Gravidez/virologia , Vacinas Virais/administração & dosagem , ViremiaRESUMO
The results of this study confirmed that dogs vaccinated subcutaneously with a commercially available multivalent vaccine containing modified-live canine distemper virus, canine adenovirus type 2, canine parvovirus type 2b, and canine parainfluenza virus antigens were protected against sequential experimental challenge 55 to 57 months after initial vaccination given at 7 to 8 weeks of age. All 10 vaccinates were protected against clinical diseases and mortality following parvovirus and infectious canine hepatitis experimental infections. All vaccinates were protected against mortality and 90% against clinical disease following distemper challenge. These data support at least a 4-year duration of immunity for these three "core" fractions in the combination vaccine.
Assuntos
Doenças do Cão/prevenção & controle , Vacinas Virais , Viroses/veterinária , Adenovirus Caninos/imunologia , Animais , Anticorpos Antivirais/biossíntese , Cinomose/prevenção & controle , Vírus da Cinomose Canina/imunologia , Doenças do Cão/imunologia , Cães , Feminino , Hepatite Infecciosa Canina/prevenção & controle , Masculino , Vacinas contra Parainfluenza/administração & dosagem , Vacinas contra Parainfluenza/imunologia , Infecções por Parvoviridae/prevenção & controle , Infecções por Parvoviridae/veterinária , Parvovirus Canino/imunologia , Parvovirus Canino/patogenicidade , Distribuição Aleatória , Fatores de Tempo , Resultado do Tratamento , Vacinação/veterinária , Vacinas Atenuadas/administração & dosagem , Vacinas Atenuadas/imunologia , Vacinas Combinadas/administração & dosagem , Vacinas Combinadas/imunologia , Vacinas Virais/administração & dosagem , Vacinas Virais/imunologia , Virulência , Viroses/imunologia , Viroses/prevenção & controleRESUMO
Since first emerging in the North American canine population in 2004, canine influenza virus (CIV) subtype H3N8 has shown horizontal transmission among dogs, with a high level of adaptation to this species. The severity of disease is variable, and coinfection by other respiratory pathogens is an important factor in the degree of morbidity and mortality. The first influenza vaccine for dogs, an inactivated vaccine containing CIV subtype H3N8, was conditionally approved by the U.S. Department of Agriculture (USDA) for licensure in May 2009 and fully licensed in June 2010. This study evaluates the efficacy of this vaccine to reduce the severity of illness in dogs cochallenged with virulent CIV and Streptococcus equi subsp. zooepidemicus.
Assuntos
Doenças do Cão/prevenção & controle , Vírus da Influenza A Subtipo H3N8/imunologia , Vacinas contra Influenza/imunologia , Infecções por Orthomyxoviridae/prevenção & controle , Infecções Estreptocócicas/veterinária , Animais , Doenças do Cão/imunologia , Doenças do Cão/patologia , Cães , Feminino , Vírus da Influenza A Subtipo H3N8/patogenicidade , Vacinas contra Influenza/administração & dosagem , Masculino , Infecções por Orthomyxoviridae/imunologia , Infecções por Orthomyxoviridae/patologia , Profilaxia Pós-Exposição , Infecções Estreptocócicas/imunologia , Infecções Estreptocócicas/patologia , Infecções Estreptocócicas/prevenção & controle , Streptococcus equi/imunologia , Streptococcus equi/patogenicidade , Estados UnidosRESUMO
Canine influenza virus (CIV) is an emerging pathogen that causes acute respiratory disease in dogs. As with any communicable disease, dog-to-dog transmission of CIV occurs when infected dogs come in contact with other susceptible dogs. We demonstrate that CIV transmission occurs readily from CIV-infected dogs to susceptible dogs following co-mingling. Four experimentally infected dogs were co-mingled with a group of eight CIV-negative dogs at 1 day post-infection and both groups were observed for CIV-associated respiratory disease. The onset of clinical signs, virus shedding, seroconversion, and appearance of lung lesions were observed earlier in experimentally infected dogs; however, the severity of the clinical signs and lung lesions were very similar in both groups. One hundred percent of the experimentally infected dogs and 75% of the contact-exposed dogs excreted virus in their nasal secretions. Additionally, 100% of experimentally infected dogs and 75% of the contact-exposed dogs exhibited varying degrees of pneumonia. Our study results demonstrate that CIV spreads readily from infected dogs to other susceptible dogs through direct contact.
Assuntos
Doenças do Cão/transmissão , Vírus da Influenza A Subtipo H3N8 , Infecções por Orthomyxoviridae/veterinária , Animais , Doenças do Cão/patologia , Doenças do Cão/virologia , Cães , Pulmão/patologia , Pulmão/virologia , Nariz/virologia , Infecções por Orthomyxoviridae/patologia , Infecções por Orthomyxoviridae/transmissão , Infecções por Orthomyxoviridae/virologia , Fatores de Tempo , Traqueia/virologia , Eliminação de Partículas ViraisRESUMO
Laboratory-reared beagles were vaccinated with a placebo or a bacterin comprised of Borrelia burgdorferi S-1-10 and ospA-negative/ospB-negative B. burgdorferi 50772 and challenged after 1 year with B. burgdorferi-infected Ixodes scapularis ticks. For the placebo recipients, spirochetes were recovered from 9 (60%) skin biopsy specimens collected after 1 month, and the organisms persisted in the skin thereafter. Ten (67%) dogs also developed joint infection (3 dogs), lameness or synovitis (7 dogs), or B. burgdorferi-specific antibodies (8 dogs). For the vaccine recipients, spirochetes were recovered from 6 (40%) skin biopsy specimens collected after 1 month. However, subsequent biopsy specimens were negative, and the dogs failed to develop joint infection (P = 0.224), lameness/synovitis (P = 0.006), or Lyme disease-specific antibody responses (P = 0.002). The bacterin provided a high level of protection for 1 year after immunization, and the addition of the OspC-producing B. burgdorferi 50772 provided enhanced protection.
Assuntos
Borrelia burgdorferi/imunologia , Doenças do Cão/prevenção & controle , Vacinas contra Doença de Lyme/imunologia , Doença de Lyme/veterinária , Animais , Anticorpos Antibacterianos/sangue , Artrite Infecciosa/microbiologia , Artrite Infecciosa/prevenção & controle , Biópsia , Borrelia burgdorferi/isolamento & purificação , Borrelia burgdorferi/patogenicidade , Cães , Ixodes/microbiologia , Doença de Lyme/prevenção & controle , Vacinas contra Doença de Lyme/administração & dosagem , Placebos/administração & dosagem , Dermatopatias Bacterianas/microbiologia , Dermatopatias Bacterianas/prevenção & controle , Fatores de TempoRESUMO
Groups of 15 laboratory-bred beagles were vaccinated and boosted with either a placebo or adjuvanted bivalent bacterin comprised of a traditional Borrelia burgdorferi strain and a unique ospA- and ospB-negative B. burgdorferi strain that expressed high levels of OspC and then challenged with B. burgdorferi-infected Ixodes scapularis ticks. The vaccinated dogs produced high titers of anti-OspA and anti-OspC borreliacidal antibodies, including borreliacidal antibodies specific for an epitope within the last seven amino acids at the OspC carboxy terminus (termed OspC7) that was conserved among pathogenic Borrelia genospecies. In addition, spirochetes were eliminated from the infected ticks that fed on the bacterin recipients, B. burgdorferi was not isolated from the skin or joints, and antibody responses associated specifically with canine infection with B. burgdorferi were not produced. In contrast, B. burgdorferi was recovered from engorged ticks that fed on 13 (87%) placebo-vaccinated dogs (P<0.0001), skin biopsy specimens from 14 (93%) dogs (P<0.0001), and joint tissue specimens from 8 (53%) dogs (P=0.0022). In addition, 14 (93%) dogs developed specific antibody responses against B. burgdorferi proteins, including 11 (73%) with C6 peptide antibodies (P<0.0001). Moreover, 10 (67%) dogs developed Lyme disease-associated joint abnormalities (P<0.0001), including 4 (27%) dogs that developed joint stiffness or lameness and 6 (40%) that developed chronic joint inflammation (synovitis). The results therefore confirmed that the bacterin provided a high level of protection against Lyme disease shortly after immunization.